marked.bio

HER2 biparatopic ADC · ADC

JSKN003

2 active trials across 2 of our biomarkers, targeting HER2. Not approved for any biomarker on marked.bio yet.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
HER2-low / ultralow (IHC 1+ or 2+/ISH-) 1 1 Phase 3
MSI-H / dMMR 1 1 Phase 3

Sponsors

Industry sponsors leading active biomarker-selected trials of JSKN003.

  1. Jiangsu Alphamab Biopharmaceuticals 1
  2. Shanghai JMT-Bio 1

Trials

2 of 2 trials shown

  1. JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-Fu, and Irinotecan

    Not yet recruiting Phase 3 Shanghai JMT-Bio Started 2026Primary completion 2027-11 NCT07384377

    JSKN003trifluridine/tipiracilregorafenibfruquintinib

    …reatment with oxaliplatin, 5-fluorouracil (such as 5-FU, Capecitabine) , irinotecan (DMMR/MSI-H subjects also need anti-PD-1/PD-L1 antibody treatment failure).

    MSI-H / dMMRHER2-positive Colorectal Cancer

  2. JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects

    Recruiting Phase 3 Jiangsu Alphamab Biopharmaceuticals Started 2023Primary completion 2026-04 NCT06079983

    JSKN003capecitabinegemcitabinevinorelbinepaclitaxeldocetaxeleribulin

    JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects

    HER2-low / ultralow (IHC 1+ or 2+/ISH-)Breast Cancer